News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
News Jazz orchestrates a $4bn cancer alliance with AbCellera Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.
News Jazz and Lilly cancer drugs cleared for use by NHS Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
News Servier snaps up cancer biotech Day One in $2.5bn deal Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
News Jazz, Roche combo cleared by FDA for lung cancer Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?
News Jazz gets FDA okay for Chimerix brain cancer drug Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.
News J&J scores EU approval for Tecvayli combo in second line Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
